Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Shanghai's Data Policy Shift Could Propel Tesla's Local Data Center Efforts 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Green industry yes, conservation no: a budget for people, not for nature 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Skechers Sales Surge as Growth Lags for Nike and Adidas; Nike Eyes 2024 Olympics 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Cancer drug pollution is a growing global concern 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
CAMBRIDGE, Mass., Aug. 03, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Canaccord Genuity 37th Annual Growth Conference in Boston on Thursday, August 10, 2017 at 9:30 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Pharmaceuticals: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
